July 24/31, 2013

Return of Secondary Genomic Findings vs Patient AutonomyImplications for Medical Care

Author Affiliations
  • 1Masters of Bioethics Program, Columbia University, New York, New York
  • 2Division of Law, Ethics, and Psychiatry, Department of Psychiatry, Columbia University, New York, New York
  • 3Department of Pediatrics, Columbia University, New York, New York
  • 4Department of Medicine, Columbia University, New York, New York

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2013;310(4):369-370. doi:10.1001/jama.2013.41709

In April 2013, the American College of Medical Genetics (ACMG) recommended that clinical laboratories conducting whole genome sequencing (WGS) and whole exome sequencing (WES) for specific clinical indications should also analyze and report any mutations identified from a list of 57 genes considered medically actionable, regardless of whether patients wish to receive the results.1 These recommendations have sparked a heated debate with profound implications for countless physicians and their patients.

First Page Preview View Large
First page PDF preview
First page PDF preview